FMP
Protagenic Therapeutics, Inc.
PTIX
NASDAQ
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
0.439 USD
-0.0091 (-2.07%)
Overall Rating
Discounted Cash Flow
Return on Equity
Return on Assets
Debt to Equity
Price to Earnings
Price to Book
We are unable to load this data!
We are unable to load the data!